EUVIMEDEUVIMED entdecken
Crossref

Rational Design of Potent and Orally Efficacious PI3Kα/δ Degrader for PIK3CA Mutant Breast Cancer without Hyperglycemic Liability

Yi Hou, Xinqing Zheng, Yiwen Zhang, Hao Shen, Chenxun Kang, Han Qin, Shuyang Cao, Yasheng Zhu, Xiao Wang, Chengliang Sun, Jiayu Ding, Zhongrui Shi und 4 weitere

Journal of Medicinal Chemistry · 09.04.2026 · 69 (7) · 7966-7994

DOI: 10.1021/acs.jmedchem.5c03368 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 09.03.2026. Verfasst von Yi Hou und 15 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Natural Medicines and Jiangsu Provincial Key Laboratory of Targetome and Innovative Drugs Medicines, China Pharmaceutical Uni…. Hauptthemen laut MEDLINE: Class I Phosphatidylinositol 3-Kinases, Breast Neoplasms, Drug Design, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: National Key Research and Development Program of China, State Key Laboratory of Natural Medicines, Natural Science Foundation of Jiangsu Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Class I Phosphatidylinositol 3-KinasesBreast NeoplasmsDrug DesignAntineoplastic AgentsPhosphoinositide-3 Kinase InhibitorsPyrimidinesQuinazolinesHumansFemaleAnimalsProteolysis Targeting ChimeraMutationMiceAdministration, OralCell Line, TumorXenograft Model Antitumor AssaysStructure-Activity RelationshipMice, Nude

Substanzen

Class I Phosphatidylinositol 3-KinasesPIK3CA protein, humanAntineoplastic AgentsProteolysis Targeting ChimeraPhosphoinositide-3 Kinase InhibitorsPyrimidinesQuinazolinescopanlisib

Autor:innen und Institutionen

  • State Key Laboratory of Natural Medicines and Jiangsu Provincial Key Laboratory of Targetome and Innovative Drugs Medicines, China Pharmaceutical University, Nanjing 211198, China.
  • Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China.
  • Institute of Innovative Drug, China Pharmaceutical University, Nanjing 211198, China.

ORCID-Profile: Kai Yuan, Peng Yang

Förderung

  • National Key Research and Development Program of China
  • State Key Laboratory of Natural Medicines
  • Natural Science Foundation of Jiangsu Province
  • National Natural Science Foundation of China
  • Fundamental and Interdisciplinary Disciplines Breakthrough Plan of the Ministry of Education of China

Zitieren

APA

Hou, Y., Zheng, X., Zhang, Y., Shen, H., Kang, C., Qin, H., Cao, S., Zhu, Y., Wang, X., Sun, C., Ding, J., Shi, Z., Wang, L., Yuan, K., Min, W., & Yang, P. (2026). Rational Design of Potent and Orally Efficacious PI3Kα/δ Degrader for PIK3CA Mutant Breast Cancer without Hyperglycemic Liability. Journal of Medicinal Chemistry, 69(7), 7966-7994. https://doi.org/10.1021/acs.jmedchem.5c03368

Vancouver

Hou Y, Zheng X, Zhang Y, Shen H, Kang C, Qin H, et al. Rational Design of Potent and Orally Efficacious PI3Kα/δ Degrader for PIK3CA Mutant Breast Cancer without Hyperglycemic Liability. Journal of Medicinal Chemistry. 2026;69(7):7966-7994. doi:10.1021/acs.jmedchem.5c03368

BibTeX
@article{Hou2026,
  author = {Hou, Yi and Zheng, Xinqing and Zhang, Yiwen and Shen, Hao and Kang, Chenxun and Qin, Han and Cao, Shuyang and Zhu, Yasheng and Wang, Xiao and Sun, Chengliang and Ding, Jiayu and Shi, Zhongrui and Wang, Liping and Yuan, Kai and Min, Wenjian and Yang, Peng},
  title = {Rational Design of Potent and Orally Efficacious PI3Kα/δ Degrader for PIK3CA Mutant Breast Cancer without Hyperglycemic Liability},
  journal = {Journal of Medicinal Chemistry},
  year = {2026},
  volume = {69},
  number = {7},
  pages = {7966--7994},
  doi = {10.1021/acs.jmedchem.5c03368}
}
Kostenlos starten →